How should midodrine be initiated, titrated, and monitored in a Parkinson’s disease patient with symptomatic orthostatic hypotension, and what are the contraindications?

Midodrine for Orthostatic Hypotension in Parkinson's Disease

Midodrine (5-10 mg three times daily) is a beneficial and FDA-approved first-line pharmacological agent for symptomatic neurogenic orthostatic hypotension in Parkinson's disease patients, but only after non-pharmacological measures have been implemented and proven insufficient. 1, 2

Initiation Strategy

Pre-Treatment Requirements

Before starting midodrine, you must:

• Confirm neurogenic orthostatic hypotension with blood pressure measurements: supine BP, then standing BP at 1 and 3 minutes (drop ≥20 mmHg systolic or ≥10 mmHg diastolic) 1
• Assess renal and hepatic function as both organs are involved in midodrine metabolism and elimination 2
• Screen for contraindications (see below)
• Document that non-pharmacological measures have failed, including: increased salt intake (6-9 g/day), fluid intake (2-3 L/day), compression garments (thigh-high or abdominal), head-up bed tilt (10°), physical counter-pressure maneuvers, and avoidance of large carbohydrate meals 1, 3

Starting Dose and Titration

Initial dose: 2.5 mg three times daily 2

• Take first dose before arising from bed in the morning
• Second dose at midday
• Final dose no later than 4 PM (at least 3-4 hours before bedtime to minimize supine hypertension) 1, 3

Titration schedule:

• Increase by 2.5 mg increments weekly based on response 4, 5
• Target dose: 10 mg three times daily (most effective dose in clinical trials) 1, 6, 4
• Maximum dose: 10 mg three times daily (higher doses increase supine hypertension risk without additional benefit) 2

For renal impairment: Start at 2.5 mg and titrate cautiously, as desglymidodrine (active metabolite) is renally eliminated 2

Monitoring Protocol

Blood Pressure Monitoring

Week 1-4 (titration phase):

• Measure 1-minute standing systolic BP 1 hour post-dose (peak effect occurs at 1 hour) 2, 4
• Measure supine BP to detect supine hypertension (target <180/110 mmHg supine) 5
• Consider 24-hour ambulatory BP monitoring if supine hypertension suspected 7

Ongoing monitoring:

• Standing BP at each clinic visit
• Home BP monitoring (supine and standing) if feasible
• Supine hypertension occurs in 8-25% of patients and is the primary dose-limiting adverse effect 4, 5

Symptom Assessment

Evaluate improvement in:

• Dizziness/lightheadedness upon standing
• Syncope/near-syncope episodes
• Weakness and fatigue
• Ability to perform activities of daily living
• Standing time tolerance 4, 5

Critical point: Continue midodrine only if patients report significant symptomatic improvement 2. The FDA indication is based on surrogate markers (standing BP), but clinical benefit must be demonstrated.

Safety Monitoring

Monitor for:

• Supine hypertension (most common serious adverse effect)
• Bradycardia (pulse slowing, increased dizziness, syncope) - discontinue if occurs 2
• Urinary retention (acts on alpha-receptors of bladder neck) - use cautiously in patients with urinary retention problems 2
• Scalp tingling/pruritus (13.5% of patients, usually mild) 4
• Piloerection (common but benign)

Absolute Contraindications

• Severe supine hypertension (>180/110 mmHg at baseline) 5
• Acute kidney disease
• Urinary retention
• Pheochromocytoma
• Thyrotoxicosis
• Persistent and excessive supine hypertension 2

Relative Contraindications and Cautions

• Cardiac disease: May enhance bradycardia, AV block, or arrhythmias when combined with cardiac glycosides 2
• Diabetes with visual problems: Use cautiously, especially if also taking fludrocortisone (increases intraocular pressure risk) 2
• Hepatic impairment: Use cautiously; liver metabolizes midodrine 2
• Renal impairment: Reduce starting dose to 2.5 mg 2

Drug Interactions to Avoid

Avoid concomitant use with:

• MAO inhibitors or linezolid (contraindicated) 2
• Alpha-adrenergic blockers (prazosin, terazosin, doxazosin) - antagonize midodrine effects 2

Use cautiously with:

• Drugs that increase BP: phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, droxidopa - monitor BP closely 2
• Fludrocortisone: Can be combined but increases supine hypertension risk; may need to reduce fludrocortisone dose or salt intake 2
• Cardiac glycosides: Monitor for bradycardia and arrhythmias 2

Expected Outcomes

Blood pressure response:

• Standing systolic BP increases by 15-30 mmHg at 1 hour post-dose 1, 2
• Effect persists for 2-3 hours 2
• Peak metabolite levels occur 1-2 hours after dosing 2

Symptom improvement:

• Significant improvement in dizziness, lightheadedness, syncope, weakness, fatigue, and standing time typically seen within 1-2 weeks 4, 5
• 77% of patients remain on therapy at 6 months when effective 5

Management of Supine Hypertension

If supine hypertension develops:

1. Ensure last dose is taken ≥4 hours before bedtime 1, 3
2. Elevate head of bed 10° during sleep 1, 6
3. Reduce or eliminate fludrocortisone if used concomitantly 2
4. Reduce salt intake if excessive 3
5. Consider short-acting antihypertensive at bedtime only in severe cases 7
6. If persistent despite measures, reduce midodrine dose or discontinue 3

Parkinson's Disease-Specific Considerations

• Neurogenic OH is common in Parkinson's disease (approximately 50% also have supine hypertension) 7
• Midodrine has been specifically studied and proven effective in Parkinson's disease patients 8
• Do not use carbidopa with droxidopa if considering combination therapy, as carbidopa decreases droxidopa effectiveness 1
• Monitor for interaction with Parkinson's medications, though midodrine does not cross blood-brain barrier significantly 2

When to Discontinue

Discontinue midodrine if:

• No significant symptomatic improvement after adequate trial (4 weeks at target dose) 2
• Bradycardia develops (pulse slowing, increased dizziness, syncope) 2
• Uncontrollable supine hypertension despite management strategies
• Urinary retention develops
• Patient develops contraindications